Dystrophin (DMD) Market Key players-Editas Medicine Inc,Genethon SA, Nippon Shinyaku Co Ltd and Pfizer Inc Forecast 2017-2021

Dystrophin (DMD)

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1473965-dystrophin-dmd-pipeline-review-h1-2017

Summary 

Dystrophin (DMD) - Dystrophin is a cytoplasmic protein. It anchors the extracellular matrix to the cytoskeleton via F-actin. It acts as ligand for dystroglycan. It act as component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma.

The report 'Dystrophin (DMD) - Pipeline Review, H1 2017' outlays comprehensive information on the Dystrophin (DMD) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Scope of the Report

- The report provides a snapshot of the global therapeutic landscape for Dystrophin (DMD) 
- The report reviews Dystrophin (DMD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Dystrophin (DMD) targeted therapeutics and enlists all their major and minor projects 

  Table of Contents 

List of Tables 
List of Figures 
Introduction 
Global Markets Direct Report Coverage 
Dystrophin (DMD) - Overview 
Dystrophin (DMD) - Therapeutics Development 
Products under Development by Stage of Development 
Products under Development by Therapy Area 
Products under Development by Indication 
Products under Development by Companies 
Products under Development by Universities/Institutes 
Dystrophin (DMD) - Therapeutics Assessment 
Assessment by Mechanism of Action 
Assessment by Route of Administration 
Assessment by Molecule Type 
Dystrophin (DMD) - Companies Involved in Therapeutics Development 
Asklepios BioPharmaceutical Inc 
BioMarin Pharmaceutical Inc 
Daiichi Sankyo Company Ltd 
Editas Medicine Inc 
Genethon SA        

  .Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1473965-dystrophin-dmd-pipeline-review-h1-2017

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)